We Don’t Kick Diabetics Out for Eating Ice Cream: Issues With Efficacy in Addiction Therapy
This article was originally published in RPM Report
An Advisory Committee review of Titan’s Probuphine highlights the difficulties of measuring addiction treatment products: how to quantify success when even opioid-positive urine samples can be a good sign.
You may also be interested in...
An advisory committee reviewing Titan’s Probuphine for abuse dependence leaned heavily on reassuring safety perspectives of two guest members invited for their particular expertise. No, they weren’t addiction experts. They were gynecologists.
There may be significant savings from eliminating wasteful packaging for high cost specialty drugs. The US FDA, however, is urging policy makers not to overlook the importance of patient safety in packaging issues.
CMS streamlined process for enhanced payments is having an impact: seven antibiotic applications for New Technology Add-On Payment status in 2021—including one for a product that has been marketed for more than five years.